$ELUT News

Elutia Inc. 2026 Q2 - Results - Earnings Call Presentation

Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript

Elutia Q2 2026 Earnings Call Transcript

Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028

Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate

Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity

Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. 2026 Q1 - Results - Earnings Call Presentation

Elutia (ELUT) Q1 2026 Earnings Transcript

Elutia Inc (ELUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Shifts

Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

Elutia to Present at the 16th Annual LD Micro Invitational May 18th

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

Elutia Reports Q1 2026 Results: Full Earnings Call Transcript

Elutia Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $3.114M Beat $3.000M Estimate

Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026